Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Medison Pharma has announced that the Pharmaceutical Administration in Israel has approved Provigil for the treatment of idiopathic hypersomnia, sleep apnea and shift work disorder.
Subscribe to our email newsletter
Baruch Elad, chairman of the Israeli Society for Sleep Research at the Israel Medical Association, said: “Provigil is activated approximately 8-12 hours after medicine intake. It helps maintain wakefulness while not affecting the ability to sleep. Taking one or two tablets during the day (or at night for nightshift workers) when people experience excessive fatigue, significantly improves their level of wakefulness, their functioning and their ability to concentrate. Provigil was proved to be safe and effective in a large number of clinical studies.”